Ignite Creation Date:
2025-12-24 @ 4:25 PM
Ignite Modification Date:
2026-01-10 @ 6:22 AM
Study NCT ID:
NCT04317066
Status:
COMPLETED
Last Update Posted:
2025-04-06
First Post:
2020-03-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-A33/KEYNOTE-A33)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-06-26
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-04-11
Completion Date Type:
ACTUAL
First Submit Date:
2020-03-19
First Submit QC Date:
None
Study First Post Date:
2020-03-20
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-03-24
Results First Submit QC Date:
None
Results First Post Date:
2025-04-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-24
Last Update Post Date:
2025-04-06
Last Update Post Date Type:
ACTUAL